Back to Agenda
Session 3: Progress Towards Structured Submission Documents: ICH M11 and the Clinical Electronic Structured Harmonized Protocol (CeSHarP)
Session Chair(s)
Stacy Tegan
Program Director
Transcelerate Biopharma, Inc., United States
All clinical content and data trace their origins to the clinical study protocol. Currently there is no internationally harmonized format or content standards for the protocol document. It’s often submitted as essentially electronic paper (PDF) with limited ability to leverage the wealth of information with. The lack of a structured, electronic, harmonized protocol contributes to inefficiencies and difficulties in reviewing and assessing clinical protocols across stakeholders. This session will provide an depth overview of the ICH M11 Clinical electronic Structured Harmonized Protocol (CeSHarP) including the latest developments on an (1) international guideline, (2) protocol template, and (3) internationally accepted technical specification (implementation guide) to promote development of structured and unstructured protocol content, application of international data standards, and interoperable/compatible electronic exchange.
Learning Objective : - Explain the benefits and opportunities that will be created for various stakeholders with electronic exchange of a an internationally harmonized, structure protocol
- Describe the planned deliverables and the latest developments on each including the ICH guideline, protocol template, and technical specification
- Consider impacts of M11 on the breadth of clinical studies in scope and its aim to accommodate regional/local regulations
Speaker(s)
Speaker
Ron Fitzmartin, PhD, MBA
FDA, United States
Senior Advisor, Office of Regulatory Operations, CBER
Speaker
Mitzi Allred, PhD
Merck & Co., Inc, United States
Director, Clinical Operations
Speaker
Mary Lynn Mercado, PhD
Novartis Pharmaceuticals Corporation, United States
Senior Group Head Regulatory Writing
Speaker
Vaishali Popat, MD, MPH
FDA, United States
Branch Chief, Office of Clinical Evaluation,Office of Therapeutic Products, CBER
Speaker
Panagiotis Telonis
European Medicines Agency, Netherlands
Scientific Administrator, Data Standardisation and Analytics Department
Have an account?